The Wnt-dependent and Wnt-independent functions of BCL9 in ...
Mar 1, 2024 · B-cell CLL/lymphoma 9 (BCL9) is considered a key developmental regulator and a well-established oncogenic driver in multiple cancer types, mainly through potentiating the …
Pharmacological inhibition of β-catenin/BCL9 ... - Science
May 8, 2019 · We identified a set of peptides, including hsBCL9 CT -24, that robustly inhibits the activity of β-cat and suppresses cancer cell growth. In animal models, these peptides exhibit …
To advance this BCL9-targeted peptide toward clinical use, we conducted extensive chemical modifications and optimizations on the original peptide, discovering a set of potent and …
Targeting tumor-intrinsic BCL9 reverses immunotherapy ...
Nov 17, 2025 · We develop a BCL9-targeting peptide, hsBCL9 Z96, which suppresses tumor growth in combination with anti-PD-L1 ab in preclinical hepatocellular carcinoma (HCC) mouse …
BCL9 as a Key Player in Wnt/β-catenin Signaling ... - Springer
Nov 12, 2025 · As a co-activator of β-catenin, BCL9 is capable of governing bone development and regeneration by augmenting the transcriptional activity of the Wnt signaling. In addition, …
BCL9 Gene: Function, Expression, and Role in Cancer
Learn about the BCL9 gene, its function, expression, and role in cancer development and progression. Explore research on BCL9 mutations, inhibitors, and potential therapeutic targets.
(PDF) Targeted Disruption of the BCL9/ -Catenin Complex ...
Aug 22, 2012 · We developed a stabilized α helix of BCL9 (SAH-BCL9), which we show targets β-catenin, dissociates native β-catenin/BCL9 complexes, selectively suppresses Wnt …